Target Audience:
This activity is intended for hematologist-oncologists, fellows, PAs, NPs, nurses, pharmacists, social workers, and other healthcare professionals involved in the care of patients with blood cancer.

Learning Objectives:
After completing this activity, the participant should be better able to:

• Explain treatment options and provide an overview of the latest developments in therapy for patients with myeloma, focusing on refractory disease
• Interpret the clinical significance of new and emerging data regarding T-cell therapy
• Identify patients who are candidates for bispecific antibody therapy
• Explain the HCP's role in preparing the patient for therapy, administering treatment, monitoring for and managing side effects
• List education and support resources for patients and caregivers and how to access them

Faculty:
Saad Z. Usmani MD, MBA, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Continuing Education Information:
There is no continuing education credit offered for this activity.

There are no fees for participating in this activity.

Providers:
This activity is provided by The Leukemia & Lymphoma Society.

This activity is supported by Janssen Oncology.

Disclaimer - The information provided in this activity is for educational purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.




Estimated time to complete activity: 0.75 hour
Date of initial release: July 20, 2023
Date of expiration: July 20, 2024

For questions, concerns, or for assistance for people with disabilities or grievances, please contact ProfEducation@LLS.org